Lipid nanoparticles containing high sterols

By adjusting the composition of lipid nanoparticles, increasing cholesterol and reducing ionizable lipids, efficient lipid nanoparticles are designed, solving the problem of insufficient targeting in nucleic acid delivery and achieving efficient liver targeting and safety .

CN118922178APending Publication Date: 2024-11-08NANOVATION THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029493.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-23
Filing Date
2023-03-22
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing lipid nanoparticle preparations have insufficient targeting in nucleic acid delivery, especially uneven distribution between the liver and spleen, affecting efficacy and safety.

Method used

By adjusting lipid composition, increasing cholesterol content and reducing ionizable lipid content, lipid nanoparticles with 49 mol% to 85 mol% cholesterol and 0.5 to 3 mol% hydrophilic polymer-lipid conjugate were designed to reduce or The lack of phospholipids improves nucleic acid encapsulation efficiency and liver targeting.

Benefits of technology

Efficient nucleic acid encapsulation and liver targeting are achieved, and the expression in the liver is increased by at least 20 times compared to traditional preparations, reducing expression in the spleen and improving efficacy and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005054687480000131
    Figure BDA0005054687480000131
  • Figure BDA0005054687480000241
    Figure BDA0005054687480000241
  • Figure BDA0005054687480000251
    Figure BDA0005054687480000251
Patent Text Reader

Abstract

The present disclosure provides a lipid nanoparticle comprising: a nucleic acid load molecule; sterols or derivatives thereof present in high levels; a neutral lipid; lipid can be ionized; and a hydrophilic polymer-lipid conjugate present in a content of between 0.5 and 3 mol%, wherein each mol% content is relative to the total lipid present in the lipid nanoparticles.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Incorporation by reference into the priority application

[0002] This application claims priority to U.S. Provisional Application Serial No. 63 / 269,815, filed on March 23, 2022, which is expressly incorporated herein by reference in its entirety. Technical Field

[0003] The present disclosure relates to lipid nanoparticle formulations for delivery of cargo, such as nucleic acids. Background Art

[0004] Lipid nanoparticle (LNP) formulations represent a revolution in nucleic acid delivery. An early example of a LNP product approved for clinical use is Onpattro TM .Onpattro TM The success of this LNP delivery system paves the way for the clinical development of the most important LNP-based COVID-19 mRNA vaccine.

[0005] Onpattro TM The LNP formulation consists of four major lipid components, namely, ionizable amino lipids, distearoylphosphatidylcholine (DSPC), cholesterol, and polyethylene glycol-conjugated lipids (PEG-lipids), with molar amounts of 50 / 10 / 38.5 / 1.5, respectively. TM It is still considered the gold standard for comparison in studies of LNP-mediated efficacy, and current LNP design methods show little deviation from the four-component system.

[0006] Among these four components, ionizable cationic lipids are considered to be important for the in vitro and in vivo activity of LNP systems. Therefore, most of the work in this field focuses on improving this lipid component. Ionizable cationic lipids are usually positively charged at low pH, which helps to associate with negatively charged nucleic acids, but are neutral at physiological pH, making them more biocompatible in biological systems. In addition, it is believed that after lipid nanoparticles are absorbed by cells through endocytosis, the ability of these lipids to ionize at low pH allows endosomal escape. This in turn allows nucleic acids to be released into the intracellular compartment.

[0007] The ionizable cationic lipids are present at 50 mol% (relative to the total lipids in the LNP) and thus account for 50 mol% of the total lipids in the LNP. TMRegarding the remaining three lipid components, it is well known that PEG-lipids can be used to prevent LNP aggregation, and cholesterol has the function of stabilizing the particles. DSPC is a bilayer-forming lipid and is generally believed to have an important structural role in the LNP membrane.

[0008] Reports indicate that in the empty Onpattro TM In the type LNP system, DSPC and cholesterol are present in the outer lipid layer, but in the system loaded with siRNA, DSPC and cholesterol are internalized in the hydrophobic core together with siRNA. At low levels of the two components (less than 40 mol% of the combined DSPC and cholesterol content), the siRNA encapsulation efficiency gradually decreases (Kulkarni et al., 2019, Nanoscale, 11: 21733-21739). The conclusion is that the presence of DSPC and cholesterol is essential for the stable encapsulation of siRNA in LNP. Due to concerns about the solubility of cholesterol, these studies only investigated LNPs with cholesterol contents up to 40 mol% (1: 1chol / DSPC). Other studies are said to show that cholesterol has limited solubility in ionizable cationic lipids above pH 7.4. It is believed that DSPC must stably retain cholesterol, and LNP preparations with chol / DSPC (mol / mol) exceeding 40:40 have not been investigated to avoid ambiguity due to the presence of excess cholesterol.

[0009] Other studies have investigated the effects of cholesterol on two-component lipoplex systems containing ionizable cationic lipids and cholesterol, but these studies used a 1:1 molar ratio of the two lipid components and did not examine the effects of increasing the cholesterol content (e.g., above 50 mol%) (Cheng and Lee, 2016, Advanced Drug Delivery Reviews, 99: 129-137; Sakurai et al., 2001, European Journal of Pharmaceutics and Biopharmaceutics, 52: 165-172; Dabkowska et al., 2012, JR Soc. Interface, 9: 548-561; Yoshioka et al., 2009, Journal of Liposome Research, 19(2): 141-147). Other studies have examined the effect of cholesterol on cubic phase formation of liposome complexes, but the lipid dispersions formed (using thin film hydration) contained high levels of phospholipids (Tenchov et al., 2006, Biophysical Journal, 91: 2508-2516).

[0010] In vivo studies examining large unilamellar vesicles (LUVs) containing phospholipids / cholesterol found that cholesterol increased the circulation life of LUVs, but the effect of cholesterol on increasing circulation life plateaued at 30 mol% (Semple et al., 1996, Biochemistry, 35(8):2521-2525).

[0011] U.S. Patent No. 11,191,849 discloses mRNA-LNP, it has 55mol% ionizable cationic lipid, 41mol% cholesterol and 3.3mol% EG2000-C-DMA.Compared with basic composition (PEG-2000-C-DMA / cationic lipid / cholesterol / DSPC of 1.6 / 55 / 33 / 11mol%), the inflammatory response after taking LNP in mice is reduced, but efficacy is not affected.The observed results are partly attributed to higher than usual PEG-lipid conjugate content (>3mol%).

[0012] Despite the above-described advances in the art, there remains a continuing need for LNP formulations having desirable properties for delivery of nucleic acids. Summary of the invention

[0013] The present disclosure solves one or more problems in the art and / or provides useful alternatives thereof.

[0014] The present disclosure is based in part on the following discovery: TM LNPs with high sterol content and low levels of ionizable lipids (e.g., significantly greater than 38.5 mol% sterols, such as cholesterol) have high nucleic acid encapsulation efficiency. In addition, despite significant differences in lipid composition from the "gold standard" benchmark, the LNPs described herein have comparable in vitro and in vivo nucleic acid delivery efficacy to Onpattro TM LNP performed comparably.

[0015] In one example of the present disclosure, LNPs with high levels of sterols or their derivatives exhibit improved targeting to the liver compared to the spleen. TM LNPs, with improved targeting to the liver compared to the spleen.

[0016] According to one embodiment of the present invention, a lipid nanoparticle is provided, comprising: a nucleic acid cargo molecule; a sterol or a derivative thereof present in a content between 49 mol% and 85 mol%; substantially no phospholipids; an ionizable lipid; and a hydrophilic polymer-lipid conjugate present in a content between 0.5 and 3 mol%, wherein each mol% content is relative to the total lipid present in the lipid nanoparticle.

[0017] In one embodiment, the sterol or derivative thereof is present in an amount of at least 50 mol % and / or the ionizable lipid is present in an amount of less than 48.5 mol %.

[0018] In another embodiment, the sterol or derivative thereof is present in an amount of at least 52 mol % and / or the ionizable lipid is present in an amount of less than 46.5 mol %.

[0019] In yet another embodiment, the sterol or derivative thereof is present in an amount of at least 54 mol % and / or the ionizable lipid is present in an amount of less than 44.5 mol %.

[0020] In another embodiment, the sterol or derivative thereof is present in an amount of at least 56 mol % and / or the ionizable lipid is present in an amount of less than 42.5 mol %.

[0021] In yet another embodiment, the sterol or derivative thereof is present in an amount of at least 58 mol % and / or the ionizable lipid is present in an amount of less than 40.5 mol %.

[0022] In another embodiment, the sterol or derivative thereof is present in an amount of at least 60 mol % and / or the ionizable lipid is present in an amount of less than 38.5 mol %.

[0023] In yet another embodiment, the sterol or derivative thereof is present in an amount of at least 62 mol % and / or the ionizable lipid is present in an amount of less than 36.5 mol %.

[0024] In yet another embodiment, the sterol or derivative thereof is present in an amount of at least 63 mol % and / or the ionizable lipid is present in an amount of less than 35.5 mol %.

[0025] In another embodiment, the sterol or derivative thereof is present in an amount of at least 64 mol % and / or the ionizable lipid is present in an amount of less than 34.5 mol %.

[0026] In yet another embodiment, the sterol or derivative thereof is present in an amount of at least 65 mol % and / or the ionizable lipid is present in an amount of less than 33.5 mol %.

[0027] In yet another embodiment, the sterol or derivative thereof is present in an amount of at least 66 mol % and / or the ionizable lipid is present in an amount of less than 32.5 mol %.

[0028] In one embodiment, the content of phospholipids is less than 1 mol%. In another embodiment, the content of phospholipids is less than 0.5 mol%.

[0029] In one embodiment, the content of the hydrophilic polymer lipid is less than 2.5 mol %.

[0030] In one embodiment, the cargo molecule is siRNA, mRNA, a carrier nucleic acid, an antisense oligonucleotide, or a nucleic acid-protein or peptide complex.

[0031] In yet another embodiment, the cargo molecule is siRNA, a carrier nucleic acid, or an antisense oligonucleotide.

[0032] In another embodiment, the ionizable lipid is an amino lipid.

[0033] In yet another embodiment, the sterol derivative is a non-cationic lipid.

[0034] In yet another embodiment, the lipid nanoparticles have an electron dense core visible by cryo-electron microscopy (cryo-TEM).

[0035] In yet another embodiment, the lipid nanoparticles are substantially free of neutral lipids.

[0036] In another embodiment, the sterol is cholesterol or the sterol derivative is a cholesterol derivative.

[0037] In yet another embodiment, the lipid nanoparticles further include tocopherol. For example, tocopherol may be present in between 0.5 and 15 mol%.

[0038] According to another aspect of the present disclosure, a method for delivering mRNA or vector DNA to produce a protein or peptide in the liver in vivo is provided, the method comprising administering to a mammal a lipid nanoparticle having at least 45 mol% sterol or a derivative thereof, a neutral lipid, and an ionizable lipid, wherein the mRNA or vector DNA is encapsulated within the lipid nanoparticle, and wherein administration of the lipid nanoparticle results in liver-specific expression of the protein or peptide encoded by the mRNA or vector DNA, wherein the lipid nanoparticle increases the expression of the protein or peptide encoded by the mRNA or vector DNA in the liver by at least 20 times compared to the spleen.

[0039] According to another aspect, a method for delivering siRNA or antisense oligonucleotides to silence a gene in the liver in vivo is provided, the method comprising administering to a mammal a lipid nanoparticle having at least 45 mol% sterols or derivatives thereof, neutral lipids, and ionizable lipids, wherein mRNA is encapsulated within the lipid nanoparticle, and wherein administration of the lipid nanoparticle results in liver-specific silencing of a protein or peptide encoded by a nucleic acid sequence, wherein the lipid nanoparticle increases silencing of the nucleic acid in the liver by at least 5-fold compared to the spleen.

[0040] According to one embodiment of the present disclosure, the increased expression of a protein or peptide encoded by the mRNA in the liver compared to the spleen is at least 10% greater than the increased expression of Onpattro LNP in the liver compared to the spleen.

[0041] According to yet another embodiment, the content of neutral lipids is between 0 and 10 mol%. In one example of the present disclosure, the content of neutral lipids is less than 8 mol%, 7 mol%, 6 mol%, 5 mol% or 4 mol%.

[0042] According to another embodiment, the sterol or its derivative is present in 45 to 80 mol %.

[0043] According to another embodiment, the sterol or its derivative is present in 49 to 65 mol %.

[0044] According to another embodiment, the hydrophilic polymer-lipid conjugate is present in the lipid nanoparticle in an amount between 0.5 and 3 mol %.

[0045] According to one embodiment, the ionizable lipid component in any of the above aspects and / or embodiments comprises a mixture of ionizable cationic lipids and ionizable anionic lipids. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1It is a figure showing that the encapsulation efficiency (%), particle size (nm) and polydispersity index (PDI) of lipid nanoparticle (LNP) preparation (DLin-MC3-DMA (MC3) ionizable lipid / cholesterol / PEG-DMG) encapsulating antisense oligonucleotide targeting c-myc with each mol% ratio of X / 98.5-X / 1.5 change with increasing cholesterol content. Cholesterol content increases from 33.5mol% to 63.5mol%. Nitrogen to phosphate (N / P) ratio is 3.

[0047] Figure 2A It is a graph showing the encapsulation efficiency (entrapment) (%), particle size (nm) and PDI of LNP (MC3 ionizable lipid / cholesterol / PEG-DMG) encapsulating firefly luciferase gene (siLuc) siRNA with respective mol% ratios of X / 98.5-X / 1.5, as the cholesterol content increases. The cholesterol content increases from 33.5mol% to 63.5mol%. The nitrogen to phosphate (N / P) ratio is 6.

[0048] Figure 2B : is a graph showing the encapsulation efficiency (%), particle size (nm) and PDI of lipid nanoparticles (MC3 ionizable cationic lipid / cholesterol / PEG-DMG) encapsulating siLuc-siRNA at respective mol% ratios of X / 98.5-X / 1.5 as the MC3 ionizable cationic lipid content increases. The ionizable cationic lipid content increases from 5mol% to 45mol%. The nitrogen to phosphate (N / P) ratio is 6.

[0049] Figure 3 The results show that the MC3 ionizable cationic lipid / cholesterol / PEG-DMGLNP with a molar ratio of 35 / 63.5 / 1.5 was compared with Onpattro TM Figure 3. Luminescence in vitro of Huh7 cells as a function of mRNA dose after treatment with LNP formulation (50 / 10 / 38.5 / 1.5 of MC3 / DSPC / cholesterol / PEG-DMG; mol / mol). The nitrogen to phosphate (N / P) ratio was 6.

[0050] Figure 4A It is a figure showing the encapsulation efficiency (%), particle size (nm) and PDI of LNP (MC3 ionizable lipid / cholesterol / PEG-DMG) encapsulating firefly luciferase mRNA with respective mol% ratios of X / 98.5-X / 1.5 changing with increasing cholesterol content. Cholesterol content increased from 53.5mol% to 83.5mol%. Nitrogen to phosphate (N / P) ratio was 6.

[0051] Figure 4B It is a figure showing that the encapsulation efficiency (%), particle size (nm) and PDI of lipid nanoparticles (MC3 ionizable cationic lipid / cholesterol / PEG-DMG) encapsulating firefly luciferase mRNA with respective mol% ratios of X / 98.5-X / 1.5 change with the increase of MC3 ionizable cationic lipid content. The ionizable cationic lipid content increases from 15mol% to 45mol%. The nitrogen to phosphate (N / P) ratio is 6.

[0052] Figure 5A The results show that the firefly luciferase mRNA was encapsulated in LNPs (MC3 ionizable cationic lipid / cholesterol / PEG-DMG) with respective mol% ratios of X / 98.5-X / 1.5 compared with Onpattro TM Figure 3. In vivo luminescence of luciferase mRNA extracted from CD-1 mouse livers following treatment with a formulation (50 / 10 / 38.5 / 1.5 of MC3 / DSPC / cholesterol / PEG-DMG; mol / mol). The nitrogen to phosphate (N / P) ratio was 6.

[0053] Figure 5B The results are shown in Figure 2. The results show that the luciferase mRNA was significantly different when LNPs (MC3 ionizable cationic lipid / cholesterol / PEG-DMG) were used in the respective mol% ratios of X / 98.5-X / 1.5 compared to Onpattro TM Figure 2. In vivo luminescence of luciferase mRNA extracted from CD-1 mouse spleens treated with a formulation (MC3 / DSPC / cholesterol / PEG-DMG at 50 / 10 / 38.5 / 1.5; mol / mol) as cholesterol content increased. The nitrogen to phosphate (N / P) ratio was 6.

[0054] Figure 5C The results are shown in Figure 2. The results show that the luciferase mRNA was significantly different when LNPs (MC3 ionizable cationic lipid / cholesterol / PEG-DMG) were used in the respective mol% ratios of X / 98.5-X / 1.5 compared to Onpattro TM Figure 3. In vivo luminescence of luciferase mRNA extracted from CD-1 mouse livers following treatment with a formulation (MC3 / DSPC / cholesterol / PEG-DMG of 50 / 10 / 38.5 / 1.5; mol / mol) as a function of increasing MC3 lipid content. The nitrogen to phosphate (N / P) ratio was 6.

[0055] Figure 5DThe results are shown in Figure 2. The results are shown in Figure 2. The results are shown in Figure 2. The results are shown in Figure 2. The results are shown in Figure 2. The results are shown in Figure 2. The results are shown in Figure 2. TM Figure 3. In vivo luminescence of luciferase mRNA extracted from CD-1 mouse spleens following treatment with a formulation (MC3 / DSPC / cholesterol / PEG-DMG of 50 / 10 / 38.5 / 1.5; mol / mol) as a function of MC3 content. The nitrogen to phosphate (N / P) ratio was 6.

[0056] Fig. 6A It is a graph showing the in vivo luminescence amount of luciferase mRNA after CD-1 mouse liver extraction after treatment with mRNA luciferase-containing LNPs having MC3 ionizable cationic lipid / cholesterol / PEG-DMG at respective ratios of 35 / 63.5 / 1.5 mol % and 35 / 61.7 / 3.3 mol %.

[0057] Figure 6B It is a graph showing the in vivo luminescence amount of luciferase mRNA after spleen extraction from CD-1 mice after treatment with mRNA luciferase-containing LNPs having MC3 ionizable cationic lipid / cholesterol / PEG-DMG at respective ratios of 35 / 63.5 / 1.5 mol % and 35 / 61.7 / 3.3 mol %.

[0058] Fig. 7A Is the display Onpattro TM Figure 3 shows the encapsulation efficiency (%), particle size (nm) and PDI of (MC3 / Chol / DSPC / PEG-DMG; 50 / 38.5 / 10 / 1.5mol%), MC3 / Chol / PEG-DMG (42 / 56.5 / 1.5mol%), MC3 / DSPC / Chol / PEG-DMG (42 / 3 / 53.5 / 1.5mol%) and MC3 / SPC-Chol(H-001) / Chol / PEG-DMG (42 / 3 / 53.5 / 1.5mol%). The lipid nanoparticles encapsulate mRNA encoding luciferase and the N / P is 6.

[0059] Figure 7B Onpattro was shown to be using LNPs containing mRNA luciferase TMFigure 3. In vivo luminescence of luciferase mRNA extracted from CD-1 mouse liver after treatment with (MC3 / Chol / DSPC / PEG-DMG; 50 / 38.5 / 10 / 1.5 mol%), MC3 / Chol / PEG-DMG (42 / 56.5 / 1.5 mol%), MC3 / DSPC / Chol / PEG-DMG (42 / 3 / 53.5 / 1.5 mol%) and MC3 / SPC-Chol(H-001) / Chol / PEG-DMG (42 / 3 / 53.5 / 1.5 mol%).

[0060] Figure 7C Onpattro was shown to be using LNPs containing mRNA luciferase TM Figure 3. In vivo luminescence of luciferase mRNA after extraction of spleen from CD-1 mice after treatment with (MC3 / Chol / DSPC / PEG-DMG; 50 / 38.5 / 10 / 1.5mol%), MC3 / Chol / PEG-DMG (42 / 56.5 / 1.5mol%), MC3 / DSPC / Chol / PEG-DMG (42 / 3 / 53.5 / 1.5mol%) and MC3 / SPC-Chol(H-001) / Chol / PEG-DMG (42 / 3 / 53.5 / 1.5mol%).

[0061] Fig. 8A Is the display Onpattro TM Figure 2 shows the encapsulation efficiency (%), particle size (nm) and PDI of the formulations (MC3 / Chol / DSPC / PEG-DMG; 50 / 38.5 / 10 / 1.5 mol%) and MC3 / SPC-Chol conjugate / Chol / PEG-DMG 42 / 3 / 53.5 / 1.5 mol% at N / P of 5, 6, 7, 8 and 9. Lipid nanoparticles encapsulate mRNA encoding luciferase. Onpattro TM The N / P of the preparation is 6.

[0062] Figure 8B Onpattro was shown to be using LNPs containing mRNA luciferase TM Figure 3. In vivo luminescence of luciferase mRNA extracted from CD-1 mouse liver after treatment with (MC3 / Chol / DSPC / PEG-DMG; 50 / 38.5 / 10 / 1.5 mol%) and MC3 / SPC-Chol conjugate / Chol / PEG-DMG 42 / 3 / 53.5 / 1.5 mol% formulations at N / P of 5, 6, 7, 8, and 9. Lipid nanoparticles encapsulate mRNA encoding luciferase. Onpattro TM The N / P of the preparation is 6.

[0063] Figure 8C Onpattro was shown to be using LNPs containing mRNA luciferase TM Figure 2. In vivo luminescence of luciferase mRNA from spleen extracted from CD-1 mice after treatment with (MC3 / Chol / DSPC / PEG-DMG; 50 / 38.5 / 10 / 1.5 mol%) and MC3 / SPC-Chol conjugate / Chol / PEG-DMG 42 / 3 / 53.5 / 1.5 mol% formulations at N / P of 5, 6, 7, 8, and 9. Lipid nanoparticles encapsulate mRNA encoding luciferase. Onpattro TM The N / P of the preparation is 6.

[0064] Fig.9A Is the display Onpattro TM Figure 3 shows the encapsulation efficiency (%), particle size (nm) and PDI of three MC3 / Chol / SPC-Chol / PEG-DMG formulations (MC3 / Chol / DSPC / PEG-DMG; 50 / 38.5 / 10 / 1.5mol%) and PEG-DMG content of 1.0mol% (42 / 54 / 3 / 1.0mol:mol); 1.5mol% (42 / 53.5 / 3 / 1.5mol:mol) and 2.0mol% (42 / 53.0 / 3 / 2.0). Lipid nanoparticles encapsulate mRNA encoding luciferase. The N / P of each formulation is 6.

[0065] Fig. 9B Onpattro was shown to be using LNPs containing mRNA luciferase TM Figure 2. In vivo luminescence of luciferase mRNA extracted from CD-1 mouse liver after treatment with three MC3 / Chol / SPC-Chol / PEG-DMG formulations (MC3 / Chol / DSPC / PEG-DMG; 50 / 38.5 / 10 / 1.5 mol%) and PEG-DMG content of 1.0 mol% (42 / 54 / 3 / 1.0 mol:mol); 1.5 mol% (42 / 53.5 / 3 / 1.5 mol:mol) and 2.0 mol% (42 / 53.0 / 3 / 2.0). Lipid nanoparticles encapsulate mRNA encoding luciferase.

[0066] Fig. 10A is a graph showing the physicochemical characteristics of mRNA preparations, which shows that Onpattro TMThe encapsulation efficiency (%), particle size (nm) and PDI of the formulations (MC3 / Chol / DSPC / PEG-DMG; 50 / 38.5 / 10 / 1.5 mol%) and ionizable cationic lipid / SPC-Chol / Chol / PEG-DMG of 42 / 2.7 / 54.3 / 1.0 mol%. As described in Example 8, the ionizable cationic lipids are norMC3, C108, C109, C123, C124, C136, C137 and C142.

[0067] Fig. 10B Onpattro was shown to be using LNPs containing mRNA luciferase TM A graph of the in vivo luminescence of luciferase mRNA extracted from the liver of CD-1 mice after treatment with a high cholesterol preparation (MC3 / Chol / DSPC / PEG-DMG; 50 / 38.5 / 10 / 1.5 mol%) and an ionizable cationic lipid / SPC-Chol / Chol / PEG-DMG of 42 / 2.7 / 54.3 / 1.0 mol% as described in Example 8.

[0068] Fig. 10C Onpattro was shown to be using LNPs containing mRNA luciferase TM A graph of the in vivo luminescence of luciferase mRNA after extracting spleen from CD-1 mice after treatment with a high cholesterol preparation of ionizable cationic lipid / SPC-Chol / Chol / PEG-DMG of 42 / 2.7 / 54.3 / 1.0 mol % as described in Example 8.

[0069] Fig.11A is a graph showing the physicochemical characteristics of plasmid DNA preparations, which shows that Onpattro TM The encapsulation efficiency (%), particle size (nm) and PDI of the formulations (MC3 / Chol / DSPC / PEG-DMG; 50 / 38.5 / 10 / 1.5 mol%) and ionizable cationic lipid / SPC-Chol / Chol / PEG-DMG of 42 / 2.7 / 54.3 / 1.0 mol%. As described in Example 8, the ionizable cationic lipids are norMC3, C123, C124 and C136. The N / P ratio is 6.

[0070] Fig. 11B Figure 2 shows the effect of ionizable cationic lipids (nMC3, C123, 124 and 136) / H-001 / cholesterol / PEG-DMG LNPs with a molar ratio of 42 / 2.7 / 54.3 / 1.0 compared to OnpattroTM Figure 3. Luminescence in vitro of Huh7 cells treated with LNP formulation (MC3 / DSPC / cholesterol / PEG-DMG 50 / 10 / 38.5 / 1.5; mol / mol) as a function of plasmid DNA dose. N / P ratio was 6.

[0071] Fig.12 It is a figure showing the physicochemical characteristics of siRNA formulations, which shows the encapsulation efficiency (%), particle size (nm) and PDI of the formulations with ionizable cationic lipids / SPC-Chol / Chol / PEG-DMG being 42 / 2.7 / 54.3 / 1.0mol%. As described in Example 8, the ionizable cationic lipids are nMC3, C123, C124 and C136. The N / P ratio is 9.

[0072] Fig.13A is a graph showing the physicochemical characteristics of mRNA formulations, which shows that the formulations with ionizable cationic lipid / SPC-Chol / Chol / PEG-DMG of 42 / 2.7 / 54.3 / 1.0 mol% and Onpattro TM The encapsulation efficiency (%), particle size (nm) and PDI of the nanostructured particles were analyzed. The N / P ratio was 6.

[0073] Fig. 13B Figure 2 shows the effect of nMC3 / H-001 / cholesterol / PEG-DMG with a molar ratio of 42 / 2.7 / 54.3 / 1.0 on the mCherry mRNA encapsulated Onpattro TM Plot of the percentage of mCherry uptake in various non-parenchymal cell types in the liver after treatment with LNP formulation (50 / 10 / 38.5 / 1.5 of nMC3 / DSPC / cholesterol / PEG-DMG; mol / mol). N / P ratio was 6.

[0074] Fig. 13C Figure 2 shows the effect of nMC3 / H-001 / cholesterol / PEG-DMG with a molar ratio of 42 / 2.7 / 54.3 / 1.0 on the mCherry mRNA encapsulated Onpattro TM Plot of the percentage of mCherry uptake in hepatocytes in the liver after treatment with LNP formulation (50 / 10 / 38.5 / 1.5 of nMC3 / DSPC / cholesterol / PEG-DMG; mol / mol). N / P ratio was 6. DETAILED DESCRIPTION

[0075] Sterol or sterol derivatives

[0076] As described herein, the LNPs of the present disclosure have significantly superior properties over conventional four-component Onpattro TMThe level of sterol or sterol derivative used in the sample preparation.

[0077] The term "sterol" refers to naturally occurring or synthetic steroids. The term includes phytosterols, zoosterols, and their derivatives.

[0078] The term "sterol derivative" refers to modified sterols or their precursors, including triterpenes.

[0079] The term "cholesterol" refers to a naturally occurring or synthetic compound having a gonane backbone and a hydroxyl moiety attached to one of its rings (usually the A ring).

[0080] The LNPs may alternatively or additionally comprise a “cholesterol derivative.” Cholesterol derivatives may be naturally occurring or artificial, and include, but are not limited to, cholesterol molecules having a sterane structure and one or more additional functional groups.

[0081] In another embodiment, the LNP may comprise triterpenes. Non-limiting examples include squalene, achilleol A, polypodatetraene, malabaricanes, lanostane, cucuribitacin, hopane, oleanane, and urosolic acid.

[0082] LNP can also comprise tocopherol as another component.In certain embodiments, the cholesterol derivative is a phytosterol.The phytosterol can be beta-sitosterol, 3-sitosterol, campesterol, stigmasterol, fucosterol or stigmastanol or its salt or ester.

[0083] In certain embodiments, the cholesterol derivative is selected from β-sitosterol, β-sitosterol acetate, 3-sitosterol, campesterol, stigmasterol, fucosterol, or stigmasterol, dihydrocholesterol, ent-cholesterol, epi-cholesterol, streptosterol, cholestanol, cholestanone, cholestenone, cholesteryl-2′-hydroxyethyl ether, cholesteryl-4′-hydroxybutyl ether , 3β[N-(N′N′-dimethylaminoethyl)carbamoylcholesterol (DC-Chol), 24(S)-hydroxycholesterol, 25-hydroxycholesterol, 25(R)-27-hydroxycholesterol, 22-oxacholesterol, 23-oxacholesterol, 24-oxacholesterol, cycloartenol, 22-ketosterol, 20-hydroxysterol, 7-hydroxycholesterol, 19-hydroxycholesterol, 22-hydroxycholesterol, 25-hydroxycholesterol sterols, 7-dehydrocholesterol, 5α-cholest-7-en-3β-ol, 3,6,9-trioxaoctane-1-ol-cholesteryl-3e-ol, dehydroergosterol, 9,11-dehydroergosterol, dehydroepiandrosterone, lanosterol, dihydrolanosterol, lanostenol, lumisterol, sitocalciferol, calcipotriol, coprosta nol), cholecalciferol, lupeol, ergocalciferol, 22-dihydroergocalciferol, ergosterol, brassicasterol, tomatidine, tomatine, ursolic acid, cholic acid, chenodeoxycholic acid, zymosterol, diosgenin, fucosterol, fecosterol, daucosterol, or their salts or esters.

[0084] The sterol or cholesterol derivative may be conjugated to another moiety such as an amino acid or an alkyl group.

[0085] In one embodiment, cholesterol or a derivative thereof is present at 48 mol % to 85 mol %, 50 mol % to 85 mol %, 52 mol % to 80 mol %, 54 mol % to 80 mol %, 56 mol % to 80 mol %, 58 mol % to 80 mol %, 60 mol % to 80 mol % or 62 mol % to 80 mol % of cholesterol or a derivative thereof based on the total lipid present in the lipid nanoparticle.

[0086] In another embodiment, cholesterol or its derivatives are present with being greater than 48mol%, 49mol%, 50mol%, 51mol%, 52mol%, 53mol%, 54mol%, 55mol%, 56mol%, 57mol%, 58mol%, 59mol%, 60mol%, 61mol% or 62mol%. The upper limit of cholesterol or cholesterol derivative content can be 88mol%, 87mol%, 86mol%, 85mol%, 84mol%, 83mol%, 82mol%, 81mol%, 80mol%, 79mol%, 78mol%, 77mol%, 76mol% or 75mol%. Cholesterol or cholesterol derivative content can include any combination of aforementioned lower limit and upper limit.

[0087] In one embodiment, cholesterol is present at 48 mol % to 85 mol %, 50 mol % to 85 mol %, 52 mol % to 80 mol %, 54 mol % to 80 mol %, 56 mol % to 80 mol %, 58 mol % to 80 mol %, 60 mol % to 80 mol % or 62 mol % to 80 mol % cholesterol based on the total lipids present in the lipid nanoparticles.

[0088] In another embodiment, cholesterol exists with being greater than 48mol%, 49mol%, 50mol%, 51mol%, 52mol%, 53mol%, 54mol%, 55mol%, 56mol%, 57mol%, 58mol%, 59mol%, 60mol%, 61mol% or 62mol%.The upper limit of cholesterol content can be 88mol%, 87mol%, 86mol%, 85mol%, 84mol%, 83mol%, 82mol%, 81mol%, 80mol%, 79mol%, 78mol%, 77mol%, 76mol% or 75mol%.Cholesterol content can include any combination of aforementioned lower limit and upper limit.

[0089] Tocopherol includes α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol or salts or esters thereof.Tocopherol may be present in 0.5 mol% to 20 mol%, 1 mol% to 15 mol%, or 2 mol% to 10 mol%.

[0090] In some embodiments, LNP comprises low level of cholesterol ester, and described cholesterol ester comprises fatty acid conjugated via ester group.For example, cholesterol ester content can be less than 10mol%, less than 8mol%, or less than 5mol%, or less than 2mol%.

[0091] In another embodiment, LNP has low levels of cationic cholesterol lipids, such as 3β-[N-(N',N'-dimethylaminoethyl)-carbamoyl] cholesterol hydrochloride (DC cholesterol). For example, the cationic cholesterol content can be less than 10 mol%, less than 8 mol%, less than 5 mol%, or less than 2 mol%.

[0092] Ionizable lipids

[0093] LNP of the present disclosure has ionizable lipids, which include a lipid or a combination of two or more such lipids. Ionizable lipids can be charged at low pH, and substantially without net charge at physiological pH. This allows electrostatic interaction to occur between lipid and negatively charged nucleic acid payload during initial formulation. Because ionizable lipids approach neutrality at physiological pH, toxicity and renal clearance are reduced. Without being limited by theory, after cells are taken up by endocytosis, the acidic environment of endosomes causes the net positive charge of ionizable amino lipids to increase, which promotes fusion with the anionic lipids of endosomal membranes and subsequent membrane instability, and nucleic acid-based therapeutic agents are released into the cytoplasm to play their role.

[0094] In certain embodiments, it is desirable to include an ionizable lipid less than 50mol% in the LNP. In certain embodiments, the content of ionizable lipid is 5mol% to 50mol%, or 8mol% to 47mol%, or 10mol% to 50mol%, or 15mol% to 45mol%, or 15mol% to 35mol% of the total lipid present in the lipid nanoparticle.

[0095] In certain embodiments, the content of ionizable lipids can be less than 48mol%, less than 45mol%, less than 40mol%, less than 35mol%, less than 30mol%, less than 25mol%, less than 20mol%, less than 15mol%, less than 10mol%, or less than 5mol%. In certain embodiments, the content of ionizable lipids can be greater than 5mol%, greater than 8mol%, greater than 10mol%, greater than 12mol%, greater than 14mol%, greater than 15mol%, greater than 16mol%, greater than 18mol%, or greater than 20mol%. Any upper limit can be combined with any lower limit to reach the content of suitable ionizable lipids in LNP.

[0096] As used herein, the term "cationic lipid" refers to a lipid that is in an electrostatically neutral form at a given pH (e.g., physiological pH) and can accept or donate protons to become electrostatically positively charged, and whose electrostatically neutral form has a calculated logarithm of the partition coefficient between water and 1-octanol (i.e., cLogP) greater than 8. In some embodiments, the pKa of the cationic lipid is between 5.0 and 7.0.

[0097] In some embodiments, cationic lipids have amino groups. In some cases, cationic lipids include protonable tertiary amine (e.g., pH titratable) head groups, C16 to C18 alkyl chains, ether linkages between their head groups and alkyl chains, and 0 to 3 double bonds. Such lipids include, but are not limited to, sulfur lipids, such as MF019 and DODMA described herein. Other lipids that can be used in the practice of the present disclosure include MC3 and KC2 type lipids, which are well known to those skilled in the art. In a further embodiment, ionizable lipids are selected from one or more lipids described in the following: WO 2022 / 246555; WO 2022 / 246568; WO 2022 / 24657; PCT / CA2023 / 050129 filed on January 31, 2023; WO2022 / 155728; 63 / 340,687 filed on May 11, 2022; 63 / 410,281 filed on September 27, 2022; 63 / 410,261 filed on September 27, 2022; 63 / 434,506 filed on December 22, 2022; 63 / 410,273 filed on September 27, 2022; and 63 / 445,854 filed on February 15, 2023, each of which is incorporated herein by reference.

[0098] In one embodiment, the ionizable cationic lipid comprises an ionizable amino head group and at least two lipophilic groups, wherein at least one lipophilic group comprises a heteroatom, such as an ester or one or more sulfur atoms. In some embodiments, at least one lipophilic group comprises distal branches and / or one or more cyclic groups. Examples of ionizable cationic lipids comprising an ionizable amino head group and two lipophilic chains, wherein at least one chain comprises one or more sulfur atoms and / or ester groups, are described in co-owned and co-pending 63 / 340,687 filed on May 11, 2022; 63 / 410,281 filed on September 27, 2022; 63 / 410,261 filed on September 27, 2022; 63 / 434,506 filed on December 22, 2022; and 63 / 410,273 filed on September 27, 2022. Functional groups comprising one or more heteroatoms can be biodegraded in vivo.

[0099] In certain embodiments, it is desirable to include less than 50mol% of the cationic lipid in the LNP. That is, the content of the cationic lipid can be less than 50mol%, less than 45mol%, less than 40mol%, less than 35mol%, less than 30mol%, less than 25mol%, less than 20mol%, less than 15mol%, less than 10mol% or less than 5mol%.

[0100] In certain embodiments, the cationic lipid is present in an amount of 5 mol% to 50 mol%, or 8 mol% to 47 mol%, or 10 mol% to 50 mol%, or 15 mol% to 45 mol%, or 15 mol% to 35 mol% of the total lipid present in the lipid nanoparticle.

[0101] The ionizable lipid component can include ionizable anionic lipids as part of the content of ionizable lipids. The example of such lipids is cholesterol succinate monoester (CHEMS). Other examples of ionizable anionic lipids are described in the co-pending and co-owned U.S. provisional patent entitled "Ionizable Anionic Lipids" filed on March 23, 2023, which is incorporated herein by reference in its entirety.

[0102] Hydrophilic polymer-lipid conjugates

[0103] In one embodiment, lipid nanoparticles include hydrophilic polymer lipid conjugates that can be incorporated into LNP. The conjugate includes the lipids that form vesicles with polar head groups, and the hydrophilic polymer chains that are covalently attached to head groups. The example of hydrophilic polymers includes polyethylene glycol (PEG), polyvinyl pyrrolidone, polyvinyl methyl ether, polyhydroxypropyl methacrylate, polyhydroxypropyl methacrylamide, polyhydroxyethyl acrylate, polymethacrylamide, polydimethylacrylamide, polymethyl oxazoline, polyethyl oxazoline, polyhydroxyethyl oxazoline, polyhydroxypropyl oxazoline, polysarcosine and polyaspartamide (polyaspartamide). In another embodiment, the hydrophilic polymer lipid conjugate is a PEG-lipid conjugate. The hydrophilic polymer lipid conjugate can also be naturally occurring or synthetic molecules containing oligosaccharides, for example, such as monosialoganglioside (G M1 ). The ability of a given hydrophilic polymer lipid conjugate to enhance the circulation life of the LNPs herein can be readily determined by one skilled in the art using known methods.

[0104] The hydrophilic polymer lipid conjugate may be present in the nanoparticle at 0.5 mol% to 5 mol%, or 0.5 mol% to 3 mol%, or 0.5 mol% to 2.5 mol%, or 0.5 mol% to 2.0 mol%, or 0.5 mol% to 1.8 mol% of the total lipid.

[0105] In another embodiment, the hydrophilic polymer-lipid conjugate is a PEG-lipid conjugate, which can be present in the nanoparticle at 0.5 mol% to 5 mol%, or 0.5 mol% to 3 mol%, or 0.5 mol% to 2.5 mol%, or 0.5 mol% to 2.0 mol%, or 0.5 mol% to 1.8 mol% of the total lipid.

[0106] As described below, the hydrophilic polymer-lipid conjugate can be conjugated to a targeting ligand at its distal end.

[0107] Low phospholipid content

[0108] Lipid nanoparticles are "essentially free of phospholipids", meaning that the lipid nanoparticles have less than 3mol% of phospholipids, such as neutral phospholipids. In one example, the lipid nanoparticles have a phospholipid content of 3mol% or less. The example of neutral phospholipids includes phosphatidylcholine or phosphatidylethanolamine, such as distearoylphosphatidylcholine (DSPC), distearoylphosphatidylethanolamine (DSPE), dioleoylphosphatidylethanolamine (DOPE), dioleoylphosphatidylcholine (DOPC), 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC), dipalmitoyl-phosphatidylcholine (DPPC). In certain embodiments, phospholipids are phospholipid-sterol conjugates, such as SPC-cholesterol, OPC-cholesterol or PPC-cholesterol conjugates. In addition, phospholipid-sterol conjugates are described in US2011 / 0177156, which is incorporated herein by reference.

[0109] An example of a suitable phospholipid for the SPC-Chol conjugate is NTX-H-0001 listed below:

[0110]

[0111] In one embodiment, the lipid nanoparticle has less than 2.9, 2.8, 2.7, 2.6, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1 or 0 mol% of phospholipids. Most advantageously, LNP does not contain phospholipids, but a small amount of phospholipids may not affect the LNP properties described herein.

[0112] In some examples of the present disclosure, it has been found that relative to Onpattro TM , adding a small amount of phospholipids to high-sterol-containing LNPs can improve liver targeting.

[0113] In another embodiment, the lipid nanoparticles are "substantially free of neutral lipids", meaning that the lipid nanoparticles have less than 3 mol% of any neutral lipid, other than cholesterol or cholesterol derivatives. The term "neutral lipid" refers to any of a number of lipid species, including vesicle-forming lipids, that exist in an uncharged or neutral zwitterionic form at physiological pH. In another example, the lipid nanoparticles have less than 8, 6, 4, or 2 mol% of neutral lipids, such as phospholipids and / or phospholipid conjugates.

[0114] The example of neutral lipids includes sphingomyelin, diacylphosphatidylcholine, such as distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC) and dipalmitoyl-phosphatidylcholine (DPPC), diacylphosphatidylethanolamine, such as dioleoylphosphatidylethanolamine (DOPE), ceramide, cephalin, triglyceride and diacylglycerol. In certain embodiments, neutral lipid is phospholipid-sterol conjugate, such as SPC-cholesterol or PPC-cholesterol conjugate or those described in US2011 / 0177156.

[0115] An example of a suitable neutral lipid for the SPC-Chol conjugate is NTX-H-0001 listed above.

[0116] In one embodiment, the lipid nanoparticle has less than 2.9, 2.8, 2.7, 2.6, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1 or 0 mol% of any neutral lipid. Most advantageously, the LNP does not contain neutral lipids, but a small amount of neutral lipids can be included in the formulation without affecting the LNP properties described herein.

[0117] Additional components

[0118] The LNPs may comprise additional lipid components or modifications to sterols (eg, cholesterol), sterol derivatives (eg, cholesterol derivatives), and / or hydrophilic polymer-lipid conjugates.

[0119] For example, the surface of LNP can be grafted to include targeting ligands. Targeting ligands can be conjugated with cholesterol, cholesterol derivatives and / or hydrophilic polymer-lipid conjugates. Targeting ligands can be conjugated with the distal end of hydrophilic polymer-lipid conjugates. Targeting ligands can be used for receptors on in vivo targeting cells. In certain embodiments, targeting ligands can be combined with any amount of phospholipids that may be included in LNP. In these embodiments, phospholipid-targeting ligand conjugates are usually present in a content less than 3mol%.

[0120] Ligands include peptides, polypeptides or proteins, and include antibodies or fragments thereof. In one embodiment, the ligand can be a single chain antibody fragment.

[0121] Nanoparticle preparation

[0122] Lipid nanoparticles can be prepared using any of a variety of suitable methods (e.g., rapid mixing / ethanol dilution method). Examples of preparation methods are described in Jeffs, LB, et al., Pharm Res, 2005, 22(3): 362-72; and Leung, AK, et al., The Journal of Physical Chemistry. C, Nanomaterials and Interfaces, 2012, 116(34): 18440-18450, each of which is incorporated herein by reference in its entirety.

[0123] For example, the method for preparing lipid nanoparticles can include dissolving lipid components (e.g., ionizable lipids, sterols, and hydrophilic polymers-lipids) in an organic solvent (e.g., ethanol) in an appropriate ratio. Aqueous buffer is prepared separately at an appropriate pH to ensure that the head groups (e.g., amino groups) of the ionizable lipids are protonated to promote electrostatic interactions with negatively charged loads and positively charged ionizable lipids. This charge interaction improves encapsulation.

[0124] In certain embodiments, the aqueous phase is then mixed with an organic solvent-lipid mixture. The aqueous phase and the organic solvent-lipid mixture can be mixed in a mixing device (e.g., a pipeline mixer), such as a T-joint mixer (e.g., a T-tube mixer), a herringbone micromixer, an annular mixer, a multichannel vortex mixer or other suitable mixing devices known to persons skilled in the art with a dedicated pump. In certain embodiments, a mixing device refers to a device including two or more inlets and mixtures converging in a central mixing region through which the outlet of the device leaves. The formation of LNP can occur when the aqueous phase and the organic solvent-lipid mixture are mixed and / or after such mixing. (Kulkarni et al., 2019, Nanoscale, 11 (18): 9023-9031, which is incorporated herein by reference).

[0125] The aqueous phase typically comprises a buffer. Non-limiting examples of suitable buffers include MES or phosphate buffered saline (PBS). Examples of suitable solvents for preparing organic solvent-lipid mixtures are organic solvents including ethanol, isopropanol, methanol and acetone.

[0126] The aqueous phase and the organic solvent-lipid mixture can be introduced into the mixer as two separate corresponding streams via a pump. The volume flow rate of each stream can be the same or different, and the corresponding flow rate of each stream can be adjusted to achieve optimal mixing and / or LNP formation.

[0127] In some embodiments, LNPs are prepared by solvent injection. In one embodiment, this method includes dissolving lipids in an organic solvent and then gradually diluting the resulting solution with an aqueous solution (e.g., a buffer). This controlled gradual dilution is achieved by mixing an aqueous stream and a lipid stream together in a container.

[0128] The average size of the lipid nanoparticles can be between 40 and 120 nm, or between 45 and 110 nm, or any range therebetween. In another embodiment, the PDI of the lipid nanoparticles is less than 0.2, or less than 0.15, or less than 0.12, or less than 0.10. The nitrogen to phosphate ratio of the lipid nanoparticles can be 3 or 6.

[0129] LNP generally includes a "core" region, which may include an electron-dense region and an optional aqueous portion, as visible through a cryo-electron microscope. Without being restricted, the electron-dense region in the core can be partially surrounded by the aqueous portion in the enclosed space, surrounded or encapsulated by the aqueous portion in the core completely, or can have a solid core without an aqueous portion, as observed through a cryo-electron microscope. The core can include nucleic acids and ionizable lipids. In one embodiment, cholesterol, cholesterol derivatives and / or tocopherol are present in the outer lipid layer and / or the core of LNP.

[0130] In some embodiments, LNP is not a liposome complex. Liposome complexes are prepared by mixing preformed cationic liposomes with nucleic acids in an aqueous solution and may exhibit unwanted properties, such as the positioning of the load on the particle surface. Liposome complexes lack the core of the above-mentioned LNP particles. In addition, LNP has a certain size, shape and morphology, while liposome complexes lack such certain physical characteristics. (See Kubota et al., 2017, Int. J. Nanomedicine, 12: 5121-5133 and Kulkarni et al., 2018, Nucleic Acid Therapeutics, 28 (3): 146-157, both of which are incorporated herein by reference).

[0131] Thus, according to some embodiments, the LNPs disclosed herein have a determined average particle size ranging from 40 to 120 nm, or from 45 to 100 nm, or from 50 to 90 nm. In some embodiments, the LNPs herein have a PDI of less than 0.20, less than 0.18, less than 0.16, less than 0.15, or less than 0.14.

[0132] As used herein, the term "encapsulation" refers to any association of nucleic acid with any lipid component or compartment of lipid nanoparticles when the nucleic acid load is incorporated into LNP. However, this does not include the positioning of nucleic acid on the particle surface, such as liposome complexes. In some examples of the present disclosure, nucleic acid is present in the core of LNP. Without being limited by theory, nucleic acid can be present in micelles in the LNP core.

[0133] Nucleic acid cargo

[0134] In one embodiment, the load is a nucleic acid. Nucleic acids include, but are not limited to, RNA (including small interfering RNA (siRNA), small nuclear RNA (snRNA), microRNA (miRNA), messenger RNA (mRNA)) or DNA (e.g., carrier DNA or linear DNA). The nucleic acid length can vary and can include nucleic acids with a length of 1-50,000 nucleotides. The nucleic acid can be in any form, including single-stranded DNA or RNA, double-stranded DNA or RNA, or a hybrid thereof. Single-stranded nucleic acids include antisense oligonucleotides. The nucleic acid can be conjugated to another molecule (including a targeting moiety). Examples of such nucleic acid conjugates are antibody-nucleic acid conjugates or oligosaccharide-nucleic acid conjugates, such as GalNAc-nucleic acid conjugates.

[0135] In one embodiment, the load is mRNA, which includes a polynucleotide encoding at least one peptide, polypeptide or protein.mRNA includes but is not limited to small activation RNA (saRNA) and trans-amplification RNA (taRNA), as described in co-pending U.S. Provisional Application No. 63 / 195,269 entitled "mRNA Delivery Using Lipid Nanoparticles", which is incorporated herein by reference.

[0136] As used herein, mRNA includes modified and unmodified mRNA. In one embodiment, mRNA includes one or more coding regions and non-coding regions. mRNA can be purified from natural sources, produced using a recombinant expression system and optionally purified, or can be chemically synthesized.

[0137] In those embodiments where the mRNA is a chemically synthesized molecule, the mRNA may comprise nucleoside analogs, such as analogs with chemically modified bases or sugars and / or backbone modifications. In some embodiments, the mRNA is or includes the following: natural nucleosides (e.g., adenosine, guanosine, cytidine, uridine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, 2-thiocytidine, pseudouridine, and 5-methylcytidine); chemically modified bases; biologically modified bases (e.g., methylated bases); intercalated bases; modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose); and / or modified phosphate groups (e.g., phosphorothioate and 5'-N-phosphoramidite bonds).

[0138] The mRNA disclosed herein can be synthesized according to any of a variety of known methods. For example, in certain embodiments, the mRNA can be synthesized by in vitro transcription (IVT). In short, IVT is typically performed using a linear or circular DNA template containing a promoter, a pool of ribonucleotide triphosphates, a buffer system that may include DTT and magnesium ions, and an appropriate RNA polymerase (e.g., T3, T7 or SP6 RNA polymerase), DNAse I, pyrophosphatase and / or RNAse inhibitors.

[0139] In some embodiments, in vitro synthesized mRNA can be purified prior to encapsulation to remove unwanted impurities, including various enzymes and other reagents used in the mRNA synthesis process.

[0140] The present invention can be used to encapsulate mRNA of various lengths. In some embodiments, the present disclosure can be used to encapsulate in vitro synthesized mRNA with a length range of about 1-20 kb, about 1-20 kb, about 1-15 kb, about 1-10 kb, about 5-20 kb, about 5-15 Kb, about 5-12 kb, about 5-10 kb, about 8-20 kb, or about 8-15 kb.

[0141] Typically, mRNA synthesis involves the addition of a "cap" at the 5' end, and a "tail" at the 3' end. The presence of the cap is advantageous because it provides resistance to nucleases found in eukaryotic cells. The presence of the "tail" helps protect the mRNA from degradation by exonucleases.

[0142] In some embodiments, the mRNA includes a 5' and / or 3' untranslated region. In some embodiments, the 5' untranslated region includes one or more elements that affect the stability or translation of the mRNA, such as an iron response element. In some embodiments, the length of the 5' untranslated region can be between about 1 and 500 nucleotides, or between 50 and 500 nucleotides or longer.

[0143] In some embodiments, the 3' untranslated region includes one or more of the following: a polyadenylation signal, a binding site for a protein that affects the positional stability of the mRNA in the cell, or one or more binding sites for miRNA. In some embodiments, the length of the 3' untranslated region can be between 1 and 500 nucleotides, or between 50 and 500 nucleotides or longer.

[0144] In certain embodiments, while mRNA provided by an in vitro transcription reaction may be desirable, other sources of mRNA are also contemplated, such as mRNA produced by bacteria, fungi, plants, and / or animals.

[0145] The mRNA sequence may include a reporter gene sequence, although incorporation of the reporter gene sequence into the pharmaceutical formulation for administration is optional. These sequences can be incorporated into mRNA and used for in vitro studies or in vivo studies in animal models to assess expression and biodistribution.

[0146] In another embodiment, the cargo is siRNA. The siRNA is incorporated into the endogenous cellular machinery, causing mRNA degradation, thereby preventing transcription. Since RNA is easily degraded, incorporating it into a delivery vehicle can reduce or prevent this degradation, thereby facilitating delivery to the target site.

[0147] The siRNA encompassed by the embodiments of the present disclosure can be used to specifically inhibit the expression of a variety of target polynucleotides. The siRNA molecules for targeting specific polynucleotides for any treatment, prevention or diagnosis application can be easily prepared according to procedures known in the art. The siRNA target site can be selected, and the corresponding siRNA can be chemically synthesized, which is produced by in vitro transcription, or expressed from a vector or PCR product. A variety of different siRNA molecules can be used to target specific genes or transcripts. The siRNA can be a double-stranded RNA or a hybrid molecule comprising RNA and DNA, such as an RNA chain and a DNA chain. The siRNA can have a variety of lengths, such as a length of 1 to 30 nucleotides, or a length of 15 to 30 nucleic acids, or a length of 20 to 25 nucleotides. In certain embodiments, the siRNA is double-stranded and has a 3' overhanging sticky end (overhang) or a 5' overhanging sticky end. In certain embodiments, the overhanging sticky end is UU or dTdT 3'. In a specific embodiment, the siRNA includes a stem-loop structure.

[0148] In yet another embodiment, the cargo molecule is a microRNA or a small nuclear RNA. MicroRNA (miRNA) is a short non-coding RNA molecule that is transcribed by genomic DNA but is not translated into protein. These RNA molecules are believed to play a role in gene expression regulation by binding to the target mRNA region. The combination of miRNA and target mRNA may downregulate gene expression, for example, by inducing translational inhibition, deadenylation or degradation of the target mRNA. Small nuclear RNA (snRNA) is typically a longer non-coding RNA molecule involved in gene splicing. snRNA molecules may have therapeutic or diagnostic importance in diseases caused by splicing defects.

[0149] In another embodiment, the load is a DNA vector. The DNA vector of the encapsulation can be applied to the subject, for repairing, enhancing or blocking or reducing the expression of cellular proteins or peptides. In another embodiment, the DNA vector of the encapsulation can be applied to the subject to diagnose disease. The DNA vector can be positioned in the target cell (such as a cell that divides rapidly), and the expression of the encoding DNA can be used to provide a measurable signal. Therefore, the nucleotide polymer can be a nucleotide sequence comprising genomic DNA, cDNA or RNA.

[0150] As will be appreciated by those skilled in the art, a vector may encode a promoter region, an operator region, or a structural region. A DNA vector may contain double-stranded DNA or may consist of a DNA-RNA hybrid. Non-limiting examples of double-stranded DNA include structural genes, genes including operator controls and termination regions, and self-replicating systems (e.g., vector DNA).

[0151] Single-stranded nucleic acids include antisense oligonucleotides (complementary to DNA and RNA), ribozymes, and riplex-forming oligonucleotides. In order to have extended activity, single-stranded nucleic acids will most advantageously have some or all of the nucleotide bonds replaced by stable non-phosphodiester bonds, including, for example, phosphorothioate, phosphorodithioate, selenophosphate (phophoroselenate), or O-alkylphosphotriester linkages.

[0152] The DNA vector can include nucleic acids modified in one or more sugar moieties and / or one or more pyrimidine or purine bases. Such sugar modifications can include replacing one or more hydroxyl groups with halogens, alkyl groups, amines, azido groups or functionalizing them to ethers or esters. In another embodiment, complete sugars can be replaced with spatially and electronically similar structures, including azasugars and carbocyclic sugar analogs. The modification of purine or pyrimidine base moieties includes, for example, alkylated purines and pyrimidines, acylated purines or pyrimidines, or other heterocyclic substituents well known to those skilled in the art.

[0153] In certain embodiments, the DNA vector can be modified with a modified molecule (e.g., a peptide, protein, steroid, or sugar moiety). Modification of the DNA vector with such a molecule can facilitate delivery to a target site of interest. In certain embodiments, such modification translocates the DNA vector through the nucleus of the target cell. As an example, a modifier may be able to bind to a specific portion of the DNA vector (usually not encoding a gene of interest), but there are also peptides or other modifiers with a nucleus homing effect (e.g., a nuclear localization signal). A non-limiting example of a modifier is a steroid-peptide nucleic acid conjugate as described in Rebuffat et al., 2002, Faseb J. 16 (11): 1426-8 (which is incorporated herein by reference). The DNA vector may contain sequences encoding different proteins or peptides. As needed, promoters, enhancers, stress or chemically regulated promoters, antibiotic-sensitive or nutrient-sensitive regions, and therapeutic protein coding sequences may be included. Non-coding sequences may also be present in the DNA vector.

[0154] Used nucleic acid in the present disclosure can be separated from natural sources, obtain from source such as ATCC or GenBank library or prepare by synthetic method.Synthetic nucleic acid can be prepared by multiple solutions or solid phase method.Usually, solid phase synthesis is preferred.Be widely available for the known procedure of solid phase synthesis nucleic acid by phosphite triester, phosphotriester and H-phosphonate chemical composition.

[0155] In one embodiment, the DNA vector is double-stranded DNA and comprises more than 700 base pairs, more than 800 base pairs, or more than 900 base pairs, or more than 1000 base pairs.

[0156] Improvements in liver-specific expression

[0157] In some embodiments, LNPs exhibit "liver-specific expression" of a protein or peptide encoded by a cargo nucleic acid, meaning that the cargo nucleic acid increases the expression of the protein or peptide in the liver by at least 10 times, at least 20 times, at least 30 times, at least 40 times, at least 50 times, or at least 60 times compared to the spleen. In some embodiments, the cargo nucleic acid is mRNA or carrier DNA. In one example, the nucleic acid is mRNA.

[0158] In some embodiments, relative to Onpattro TM , adding a small amount of neutral lipid can improve the liver-specific expression of LNP with high level of sterol or sterol derivative. For example, the content of neutral lipid can be between 0 to 10mol%, or 0.5 to 10mol%, or 1mol% to 8mol%, or 1mol% to 5mol%, or 1mol% to 3.5mol%, to improve liver targeting.

[0159] In a further embodiment, relative to Onpattro TM , adding low levels of hydrophilic polymer lipid conjugates can improve liver-specific expression of LNPs with high levels of sterols or sterol derivatives. For example, the content of hydrophilic polymer lipid conjugates that achieve this improved liver targeting can be less than 2.5 mol%, less than 2.25 mol%, less than 2.0 mol%, less than 1.75 mol%, less than 1.5 mol%, or less than 1.25 mol%.

[0160] Alternatively or additionally, when measured under otherwise identical conditions and when the same cargo is encapsulated, expression of a protein or peptide encoded by a nucleic acid cargo (e.g., mRNA or vector DNA) in the liver compared to the spleen is increased compared to Onpattro TM The increase in expression in the LNPs in the liver compared to the spleen was at least 5% or 10% greater.

[0161] These examples are intended to illustrate the preparation of specific lipid nanoparticle formulations and their properties, but are in no way intended to limit the scope of the invention.

[0162] Unless otherwise specified, the word "a" or "an" used herein includes both the singular and the plural.

[0163] Example

[0164] Example 1: LNPs with high cholesterol levels have high encapsulation efficiency

[0165] This example examines the effects of increasing cholesterol content and decreasing ionizable lipid content on the physical properties of phospholipid-deficient lipid nanoparticles.

[0166] By injecting a certain volume of lipid mixture (ionizable lipid (DLin-MC3-DMA, "MC3" herein), cholesterol, PEG-DMG) into the aqueous phase containing nucleic acid loading material via a T-joint with a 3:1 aqueous phase: ethanol (v / v) ratio and an amine to phosphate (N / P) ratio of 6 from a final concentration of 15-45 mol% ionizable lipid dissolved in ethanol to 10 mM at respective mol% ratios of X / 98.5-X / 1.5, LNPs without phospholipids or LNPs substantially free of phospholipids with different concentrations of cholesterol were prepared. The flow rate of the lipid phase was set to 5 mL / min, and the flow rate of the aqueous phase containing mRNA dissolved in 25 mM sodium acetate (pH 4) was 15 mL / min, and the final output flow rate was 20 mL / min. The resulting preparation was then dialyzed for 24 hours with 1000 volumes of phosphate buffered saline (pH 7.4) to remove ethanol from the preparation. The nucleic acid cargo was an antisense oligonucleotide targeting c-myc or a siRNA targeting the firefly luciferase gene (siLuc).

[0167] Figure 1 Shown is the effect of increasing the mol% of cholesterol in phospholipid-free LNPs (containing ionizable lipid, cholesterol, PEG-DMG) encapsulating antisense oligonucleotides at respective mol% ratios of X / 98.5-X / 1.5 (ionizable lipid / cholesterol / PEG-DMG).

[0168] Surprisingly, the phospholipid-free LNPs with the highest load (antisense oligonucleotide) encapsulation efficiency detected in the data set contained the highest levels of cholesterol, i.e. 53.5mol%, 58.5mol% and 63.5mol%. It is noteworthy that the encapsulation efficiency of each of these preparations is close to 100%. These LNPs also show favorable PDI values ​​(less than 0.1) and suitable particle sizes (about 60nm).

[0169] Figure 2A showed that increasing cholesterol content affects the physical properties of phospholipid-free LNPs beyond Figure 1The detection range of phospholipid-free LNPs was increased from 53.5mol% to 93.5mol%. Surprisingly, when the cholesterol content of phospholipid-free LNPs was in the range of 53.5mol% to 83.5mol%, the encapsulation efficiency of the load (siLuc) was close to 100%. Within this cholesterol mol% range, LNP size and PDI were also acceptable. When higher than 83.5mol% cholesterol, LNPs showed high PDI values ​​(greater than 0.2) and LNP particle sizes greater than 100nm.

[0170] Figure 2B yes Figure 2A , but depicted as a function of ionizable lipid (MC3) content (rather than cholesterol content). TM Preparation has high-level ionizable lipid (50mol%), and all the other lipid components are DSPC (10mol%), cholesterol (38.2mol%) and PEG-DMG (1.5mol%). However, quite surprisingly, in the phospholipid-free LNP studied here, the MC3 content as low as 15mol% shows an encapsulation efficiency approaching 100% and is lower than 0.2 PDI value and a particle size within the scope of 50nm to 75nm. Data also show that the LNP with the MC3 mol% between 20% and 45mol% demonstrates approximately 100% consistent encapsulation level.

[0171] Example 2: Phospholipid-free luciferase mRNA-LNPs with high cholesterol levels and low MC3 levels have similar effects to Onpattro TM Equivalent in vitro potency of the formulations

[0172] This example shows that MC3 / cholesterol / PEG-DMG (35 / 63.5 / 1.5 mol:mol) LNPs encapsulating luciferase mRNA have similar luminescence performance to Onpattro TM The formulations had comparable in vitro potency.

[0173] MC3 / cholesterol / PEG-DMG (35 / 63.5 / 1.5 mol:mol) and Onpattro encapsulated mRNA were prepared by injecting a volume of a lipid mixture (ionizable lipid, cholesterol, PEG-DMG) at respective mol% ratios dissolved in ethanol to a final concentration of 10 mM via a T-junction at an aqueous phase:ethanol (v / v) ratio of 3:1 and an amine to phosphate (N / P) ratio of 6 into an aqueous phase containing mRNA encoding luciferase. TM(MC3 / distearoylphosphatidylcholine (DSPC) / cholesterol / PEG-DMG 50 / 10 / 38.5 / 1.5) LNP. The flow rate of the lipid phase was set to 5 mL / min, and the flow rate of the aqueous phase containing mRNA dissolved in 25 mM sodium acetate (pH 4) was 15 mL / min, with a final output flow rate of 20 mL / min. The resulting preparation was then dialyzed for 24 hours with 1000 volumes of phosphate buffered saline (pH 7.4) to remove ethanol from the preparation.

[0174] After reaching approximately 80% confluence, Huh7 cells were seeded at 8,000 cells per well in a clear flat-bottom 96-well plate. After 24 hours of growth, the initial medium was replaced with medium containing LNPs encapsulating luciferase mRNA at a dose adjustment of 0.03 μg / mL–10 μg / mL. Each cell treatment was performed in triplicate. After 24 hours, the medium was aspirated and 100 μL of Glo Lysis Buffer was added to each well. TM (Promega TM Each plate was then incubated at 37°C for 10 minutes, and 50 μL from each well was transferred to a white flat-bottom 96-well plate for luminescence measurement. 50 μL of Steady-Glo Luciferase TM The substrate was added to each well and then read using the BioTek Synergy Neo2 Hybrid Multi-Mode Reader. TM The luminescence reading is measured immediately.

[0175] Figure 3 The results shown in Figure 2 show that in the presence of MC3 / cholesterol / PEG-DMG (35 / 63.5 / 1.5 mol:mol) and Onpattro TM The luminescence intensity of luciferase expressed from mRNA was comparable across the range of LNP Luc-mRNA doses between formulations. This was somewhat surprising because the MC3 / cholesterol / PEG-DMG formulation had a higher luminescence intensity than Onpattro TM The preparation had 15 mol% less MC3 ionizable lipids and was deficient in phospholipids.

[0176] Example 3: Phospholipid-free luciferase mRNA-LNPs with high cholesterol levels and low MC3 levels have similar effects to Onpattro TM Equivalent in vivo efficacy of the formulations

[0177] This example shows that, relative to Onpattro TMCompared with encapsulating luciferase mRNA, various LNPs with high cholesterol content and reduced ionizable lipid content have similar TM The formulations had comparable in vivo efficacy.

[0178] Phospholipid-free MC3 / cholesterol / PEG-DMG (X / 98.5-X / 1.5 moles of ionizable lipid / chol / PEG-DMG) and Onpattro encapsulated Luc-mRNA were prepared as described in Example 2. TM Formulation (MC3 / Chol / DSPC / PEG-DMG of 50 / 38.5 / 10 / 1.5).

[0179] Figure 4A and 4B Biophysical data for the tested formulations are shown. Similar to the formulations tested in Example 2, albeit with correspondingly reduced levels of MC3 ionizable lipids (45 mol% to 15 mol%; see Figure 4B ), but the encapsulation efficiency of each LNP for formulations with cholesterol content of 53.5-83.5 mol% was close to 100% ( Figure 4A ). The PDI and size of each formulation tested were acceptable.

[0180] For in vivo studies, the final dose of mRNA in the formulation was 1 mg / kg of mRNA. Luc-mRNA formulations were administered to CD-1 mice, and liver and spleen were extracted 4 hours after injection. TM Steady-Glo TM The luciferase assay system measures the luminescence of mRNA.

[0181] Figures 5A-5D The amount of luminescence in the liver and spleen is shown for each preparation tested. Figure 5A and Figure 5B The luminescence intensity / mg tissue of liver and spleen is shown separately as the cholesterol content increases. As cholesterol increases from 53.5mol% to 83.5mol%, the luminescence intensity / mg liver of each formulation tested is similar. In addition, the luminescence intensity of the formulations with increased cholesterol content is similar to that of Onpattro TM The luminescence intensity of the preparations was similar. Figure 5C and Figure 5D The same data plotted as a function of increasing ionizable cationic lipid content are shown, again showing similar luminescence intensities for formulations with different ionizable cationic lipid contents. Notably, formulations with ionizable cationic lipid contents as low as 15 mol% and cholesterol contents of 83.5 mol% had luminescence intensities in liver and spleen that were generally similar to OnpattroTM This is somewhat surprising, as the latter MC3 / cholesterol / PEG-DMG formulation has a higher TM The formulation contained 35 mol% less MC3 ionizable cationic lipids and lacked phospholipids. In addition, in each case, LNPs exhibited higher mRNA luciferase expression in the liver relative to the spleen.

[0182] Example 4: Increasing the PEG-lipid content above 3 mol% reduces the luminescence intensity in vivo

[0183] Next, the effect of increasing the PEG-lipid content to above 1.5 mol% on the luminescence intensity of LNPs containing Luc mRNA in the liver and spleen was explored. The LNPs tested contained 35 / 63.5 / 1.5 mol% and 35 / 61.7 / 3.3 mol% MC3 / cholesterol / PEG-DMG and were prepared as described in Example 2. In vivo studies evaluating mRNA luminescence intensity were performed using the same method as described in Example 3 above.

[0184] Fig. 6A showed that in the liver, the luminescence intensity of LNPs containing 1.5 mol% PEG-lipid was almost two times higher than that of LNPs containing 3.3 mol% PEG-lipid. Figure 6B showed that in the spleen, the luminescence intensity of LNPs containing 1.5 mol% PEG-lipid was almost three times higher than that of LNPs containing 3.3 mol% PEG-lipid.

[0185] These results indicate that in some embodiments, the PEG-lipid content is advantageously mostly less than 3 mol%. In addition, for each formulation tested, LNPs exhibited higher mRNA luciferase expression in the liver relative to the spleen (see Fig. 6A and 6B ). Fig. 6A showed that in the liver, the luminescence intensity of LNPs containing 1.5 mol% PEG-lipid was almost two times higher than that of LNPs containing 3.3 mol% PEG-lipid. Figure 6B Show, in spleen, the luminescence intensity of LNP containing 1.5mol% PEG-lipid is almost three times higher than the luminescence intensity of LNP containing 3.3mol% PEG-lipid. These results show that in some embodiments, PEG-lipid content is mostly advantageously less than 3mol%. In addition, for each tested preparation, relative to spleen, LNP shows higher mRNA luciferase expression in liver (see Fig. 6A and 6B ).

[0186] Example 5: High sterol LNP formulations targeting the liver versus the spleen

[0187] As previously mentioned, Examples 3 and 4 above demonstrated that high sterol mRNA LNPs resulted in increased mRNA expression levels in the liver relative to the spleen in vivo (see Figures 5A-5D and Fig. 6A and 6B ).Compare Figure 5A and 5B , the luminescence intensity / mg liver of each high cholesterol LNP formulation (53.5 mol% to 83.5% cholesterol) Figure 5A ) is higher than the luminescence intensity of the same preparation / mg spleen ( Figure 5B ) is up to 1000 times higher. In the case of the respective ratios of 35 / 63.5 / 1.5mol% and 35 / 61.7 / 3.3mol% ( Fig. 6A and 6B A similar liver targeting trend was observed in the LNP formulation of ionizable cationic lipid / cholesterol / PEG-DMG.

[0188] In this example and the following examples, the effect of changing the lipid composition in high sterol LNP to enhance mRNA expression in the liver relative to the spleen was examined in more detail. LNPs were prepared as described in Example 2 above, and in vivo studies were performed to evaluate mRNA luminescence intensity in the liver and spleen using the procedures described in Example 3 above. As described above, liver and spleen were removed, and mRNA expression (luminescence intensity) was evaluated 4 hours after injection.

[0189] The inventors first tested the in vivo expression of mRNA of different levels of DSPC and SPC-cholesterol conjugates, in which one acyl chain of DSPC was replaced by cholesterol (see the structure of H-0001 above). In particular, the high cholesterol LNP formulations tested included a three-component LNP containing MC3, 56.5mol% cholesterol and 1.5mol% PEG-DMG, and two four-component high cholesterol LNPs containing 3mol% DSPC or SPC-chol conjugates (included in the formulation at the expense of cholesterol).

[0190] Table 1: Preparation of homosterol mRNA-LNP formulations for in vivo detection of liver and spleen mRNA expression in the presence or absence of phospholipids

[0191]

[0192] The formulation characteristics of each LNP, including size (nm), PDI, and encapsulation efficiency, were evaluated as described in Example 1, and the results are shown in Table 1. Fig. 7A as shown in .

[0193] High sterol formulation (sample BD) has the same TM (Sample A) Comparable mRNA expression, but surprisingly, with Onpattro TM In contrast, it was observed that the mRNA expression level of the preparation of the present invention in spleen was lower than that in liver, thus being more liver-tropic (see Figure 7B and Figure 7C ). Notably, the addition of 3 mol% phospholipids (DSPC and SPC-Chol conjugates) to the high sterol LNPs further reduced spleen activity relative to sample B lacking phospholipids (samples C and D above).

[0194] Example 6: Increasing N / P in a high sterol formulation does not affect liver activity but maintains liver tropism

[0195] To determine the effect of varying the amine to phosphate ratio (N / P) on liver targeting, 42 / 3 / 53.5 / 1.5 mol% MC3 / SPC-Chol conjugate / Chol / PEG-DMG homosterol mRNA-LNP formulations (Formulation D in Table 1) were prepared at N / P values ​​of 5, 6, 7, 8, and 9. LNPs were prepared as described in Example 2 above, and in vivo studies were performed to evaluate mRNA luminescence intensity in the liver and spleen using the procedures described in Example 3 above.

[0196] The formulation characteristics of each LNP, including size (nm), PDI, and encapsulation efficiency of mRNA encoding luciferase, were evaluated as described in Example 1, and the results are shown in Table 1. Fig. 8A as shown in .

[0197] like Figure 8B and 8C As shown in , increasing the N / P of the high sterol formulation (42 / 3 / 53.5 / 1.5 MC3 / SPC-Chol / Chol / PEG-DMG (mol:mol)) had no substantial effect on activity (mRNA expression of luciferase) in the liver or spleen. Thus, these formulations can encapsulate a wide range of N / Ps without affecting liver tropism.

[0198] Example 7: Reducing PEG-lipid in high-sterol formulations improves liver targeting

[0199] The inventors tested the in vivo expression of luciferase mRNA in liver and spleen using LNP compositions with different levels of PEG-lipids as shown in Table 2 below. In particular, the high sterol LNP formulations tested included a four-component LNP with MC3 / cholesterol / Chol / PEG-DMG, which had 42 / 55-X / 3 / X mol% of MC3 / SPC-Chol / PEG-DMG, where X was 1.0, 1.5 or 2.0 mol%.

[0200] Table 2: Preparation of LNP formulations for testing mRNA expression in the liver and spleen in vivo at different levels of PEG-lipid conjugates

[0201]

[0202] LNPs were prepared as described in Example 2 above, and in vivo studies were performed to evaluate mRNA luminescence intensity in the liver and spleen using the procedures described in Example 3 above.

[0203] The formulation characteristics of each LNP, including size (nm), PDI, and encapsulation efficiency, were evaluated as described in Example 1, and the results are shown in Table 1. Fig.9A as shown in .

[0204] Decreasing the PEG-lipid mol% in the high sterol formulation (samples BD in Table 2) resulted in increased liver activity (see Fig. 9B ). Surprisingly, compared to Onpattro TM (Sample A in Table 2), formulations with 1.0 and 1.5 mol% PEG lipid (Samples B and C in Table 2) showed higher levels of mRNA expression.

[0205] Example 8: Multiple different ionizable cationic lipids can be formulated into high-sterol mRNA lipid nanoparticles with improved liver tropism

[0206] To determine the ability of various different ionizable cationic lipids to be formulated in homosterol LNPs, a formulation of 42 / 2.7 / 54.3 / 1.0 mol% ionizable cationic lipid / SPC-Chol / Chol / PEG-DMG was prepared using ionizable cationic lipids with the following amino ionizable head groups: norMC3, C108, C109, C123, C124, C136, C137, and C142. The ionizable cationic lipids were also studied compared to Onpattro TM Improve liver activity. The control group was Onpattro TM (See Table 1 above).

[0207] Ionizable cationic lipids are listed in Table 3 below.

[0208] Table 3: Ionizable Cationic Lipids for High Sterol Formulations

[0209]

[0210] LNPs were prepared as described in Example 2 above, and in vivo studies were performed to evaluate mRNA luminescence intensity in the liver and spleen using the procedures described in Example 3 above.

[0211] The formulation characteristics of each LNP, including size (nm), PDI, and encapsulation efficiency, were evaluated as described in Example 1, and the results are shown in Table 1. Fig. 10A as shown in .

[0212] Surprisingly, compared to Onpattro TM (Sample A of Table 1), the formulations with ionizable cationic lipids containing sulfur atoms in their lipophilic chains showed higher levels of mRNA expression. The liver activity of C123, 124, 136 and 143 ionizable cationic lipids was increased by 4.2 to 6.8 times (see Fig. 10B ), while maintaining liver tropism as evidenced by low expression in spleen ( Fig. 10C ).

[0213] Example 9: Multiple different ionizable lipids can encapsulate plasmid DNA in high sterol formulations and improve in vitro transfection

[0214] The ability to encapsulate plasmid DNA in a variety of homosterol LNPs with different ionizable cationic lipids was tested. In particular, the following ionizable cationic lipids with amino ionizable head groups: nMC3, C123, C124 and C136 were used to prepare a formulation containing 42 / 2.7 / 54.3 / 1.0 mol% of ionizable cationic lipids / SPC-Chol / Chol / PEG-DMG (see Table 3 of Example 8 above for the structure). The ionizable cationic lipids were also studied compared to Onpattro TM Improve the ability of in vitro transfection. The control group was Onpattro TM (See Table 1 above).

[0215] LNPs were prepared using the procedure described in Example 2 above, except that Aldevron Gwiz-Luciferase was used. TM The plasmid replaced the luciferase mRNA and in vitro studies were performed to evaluate the luminescence intensity of Huh7 cells using the procedures described in Example 2 above.

[0216] The formulation characteristics of each LNP, including size (nm), PDI, and encapsulation efficiency, were evaluated as described in Example 1, and the results are shown in Table 1. Fig.11A as shown in .

[0217] Surprisingly, compared to Onpattro TM (Table 1, Sample A), the formulations with ionizable cationic lipids containing sulfur atoms in their lipophilic chains showed higher levels of luciferase expression. At the same dose of nMC3, C123, 124 and 136 ionizable cationic lipids, the in vitro transfection activity was increased by 1.1 to 14.7 times (see Fig. 11B ).

[0218] Example 10: Multiple different ionizable cationic lipids are able to encapsulate siRNA in a high sterol formulation

[0219] The ability to encapsulate siRNA in homosterol LNPs formulated with a variety of different ionizable cationic lipids was tested. In particular, 42 / 2.7 / 54.3 / 1.0 mol% ionizable cationic lipids / SPC-Chol / Chol / PEG-DMG LNP formulations were prepared using the following ionizable cationic lipids with amino ionizable head groups: nMC3, C123, C124, C136 (see Table 3 in Example 8 above for structure).

[0220] LNPs were prepared as described in Example 2 above, except that DNA from Integrated DNA Technologies was used. TM Luciferase mRNA was replaced by luciferase siRNA (IDT).

[0221] The formulation characteristics of each LNP, including size (nm), PDI, and encapsulation efficiency, were evaluated as described in Example 1, and the results are shown in Table 1. Fig.12 as shown in .

[0222] Example 11: High sterol LNPs exhibit similar TM Fairly hepatocyte-specific, but more liver-specific

[0223] To determine the cell specificity of homosterol LNPs, Onpattro TM Compared to (nMC3), mCherry mRNA was encapsulated in a high sterol LNP formulation of 42 / 2.7 / 54.3 / 1.0 mol% nMC3 / SPC-Chol / Chol / PEG-DMG, which was injected at a dose of 1 mg / kg before CD-1 mice were euthanized at the 24-hour endpoint. The mice were euthanized and perfused with 15 mL of cold 1x phosphate buffered saline (PBS). The liver was collected into 5 mL RPMI supplemented with 5% heat-inactivated fetal bovine serum (HI-FBS). The liver was then minced and incubated with 0.5 mg / mL type IV collagenase (Sigma-Aldrich) in RPMI. TM) and 2mg / mLDNase I (Sigma-Aldrich TM ) were digested at 37°C for 30 minutes while shaking at 200 rpm. A single cell suspension was obtained by passing the digested liver through a 70 μm sieve. The single cell suspension was then spun at 50 g for 3 minutes at 4°C to precipitate and collect the hepatocytes. The supernatant containing the non-parenchymal cell fraction was collected. The hepatocytes were then washed twice more with 10 mL of flow cytometry staining (FACS) buffer. The hepatocytes were then stained with 20% OptiPrep TM Gradient (StemCell Technologies TM , see manufacturer's protocol) to separate the non-parenchymal fraction from the liver. The cells were washed with FACS buffer and analyzed by flow cytometry (see below).

[0224] Surface staining for flow cytometry

[0225] Liver cells were resuspended in PBS containing 5% HI-FBS, 0.05% NaN3 and 2.5 mM EDTA (FACS buffer) and incubated with anti-FcgRII / RIII (2.4G2) on ice for at least 15 min. They were then incubated with conjugated antibodies to CD11b [M1 / 70], CD26 [H94-112], CD31 [MEC13.3], CD38

[90] , panCD45 [I3 / 2], CD45R (B220) [RA3-6B2], Clec4F [3E3F9], Ly6G [IA8], TCRβ [H57-597] (Thermo Fisher Scientific) TM The cells were stained with fluorescent dyes of BD Bioscience (BioLegend) for 45 minutes on ice in the dark. To exclude dead cells, fixable viability dye (Fixable Viability Dye) (Thermo Fisher Scientific, Inc., Boston, MA) was used according to the manufacturer's instructions before flow cytometry acquisition. TM ) to stain the cells.

[0226] Acquisition and analysis of flow cytometry data

[0227] Using Cytoflex LX TM Acquire flow cytometry data and use FlowJo TM (TreeStar TM ) for analysis.

[0228] LNPs were prepared as described above in Example 2, except that mCherry mRNA was substituted for luciferase mRNA.

[0229] The formulation characteristics of each LNP, including size (nm), PDI, and encapsulation efficiency, were evaluated as described in Example 1, and the results are shown in Table 1. Fig.13A as shown in .

[0230] Surprisingly, in all cell types evaluated, the high sterol preparation had similar effects to Onpattro TM (containing nMC3) equivalent mCherry expression ( Fig. 13B and 13C ). Combined Fig. 10B and 10C The data shown in (Example 8) show that with Onpattro TM Preparations with the same ionizable lipids were comparable, while increasing the tropism of cells to the liver.

Claims

1. A lipid nanoparticle comprising: Nucleic acid cargo molecules; Sterol or its derivative present in an amount between 49 mol% and 85 mol%; Essentially free of phospholipids; ionizable lipids; and a hydrophilic polymer-lipid conjugate present in an amount between 0.5 and 3 mol %, Each mol% content is relative to the total lipid present in the lipid nanoparticles.

2. The lipid nanoparticle according to claim 1, wherein the sterol or its derivative is present in an amount of at least 50 mol%.

3. The lipid nanoparticle of claim 2, wherein the ionizable lipid is present in an amount less than 48.5 mol%.

4. The lipid nanoparticle of claim 1, wherein the sterol or derivative thereof is present in an amount of at least 52 mol%.

5. The lipid nanoparticle of claim 4, wherein the ionizable lipid is present in an amount less than 46.5 mol%.

6. The lipid nanoparticle of claim 1, wherein the sterol or derivative thereof is present in an amount of at least 54 mol%.

7. The lipid nanoparticle of claim 6, wherein the ionizable lipid is present in an amount less than 44.5 mol%.

8. The lipid nanoparticle of claim 1, wherein the sterol or derivative thereof is present in an amount of at least 56 mol%.

9. The lipid nanoparticle of claim 8, wherein the ionizable lipid is present in an amount less than 42.5 mol%.

10. The lipid nanoparticle of claim 1, wherein the sterol or derivative thereof is present in an amount of at least 58 mol%.

11. The lipid nanoparticle of claim 10, wherein the ionizable lipid is present in an amount less than 40.5 mol%.

12. The lipid nanoparticle of claim 1, wherein the sterol or derivative thereof is present in an amount of at least 60 mol%.

13. The lipid nanoparticle of claim 12, wherein the ionizable lipid is present in an amount less than 38.5 mol%.

14. The lipid nanoparticle of claim 1, wherein the sterol or derivative thereof is present in an amount of at least 62 mol%.

15. The lipid nanoparticle of claim 14, wherein the ionizable lipid is present in an amount less than 36.5 mol%.

16. The lipid nanoparticle of claim 1, wherein the sterol or derivative thereof is present in an amount of at least 63 mol%.

17. The lipid nanoparticle of claim 16, wherein the ionizable lipid is present in an amount less than 35.5 mol%.

18. The lipid nanoparticle of claim 1, wherein the sterol or derivative thereof is present in an amount of at least 64 mol%.

19. The lipid nanoparticle of claim 18, wherein the ionizable lipid is present in an amount less than 34.5 mol%.

20. The lipid nanoparticle of claim 1, wherein the sterol or derivative thereof is present in an amount of at least 65 mol%.

21. The lipid nanoparticle of claim 20, wherein the ionizable lipid is present in an amount less than 33.5 mol%.

22. The lipid nanoparticle of claim 1, wherein the sterol or derivative thereof is present in an amount of at least 66 mol%.

23. The lipid nanoparticle of claim 22, wherein the ionizable lipid is present in an amount less than 32.5 mol%.

24. The lipid nanoparticle according to any one of claims 1 to 23, wherein the content of the phospholipid is less than 1 mol%.

25. The lipid nanoparticle according to any one of claims 1 to 23, wherein the content of the phospholipid is less than 0.5 mol%.

26. The lipid nanoparticle according to any one of claims 1 to 25, wherein the content of the hydrophilic polymer-lipid is less than 2.5 mol%.

27. The lipid nanoparticle of any one of claims 1 to 26, wherein the cargo molecule is siRNA, mRNA, a carrier nucleic acid, an antisense oligonucleotide, or a nucleic acid-protein or peptide complex.

28. The lipid nanoparticle of claim 27, wherein the cargo molecule is siRNA, a carrier nucleic acid or an antisense oligonucleotide.

29. The lipid nanoparticle of any one of claims 1 to 28, wherein the ionizable lipid is an amino lipid.

30. The lipid nanoparticle of any one of claims 1 to 29, wherein the sterol derivative is a non-cationic lipid.

31. A lipid nanoparticle according to any one of claims 1 to 30, wherein the lipid nanoparticle has an electron dense core visible by cryo-electron microscopy.

32. The lipid nanoparticle of any one of claims 1 to 31, wherein the lipid nanoparticle is substantially free of neutral lipids.

33. The lipid nanoparticle of any one of claims 1 to 32, wherein the sterol is cholesterol, or the sterol derivative is a cholesterol derivative.

34. The lipid nanoparticle of any one of claims 1 to 32, further comprising tocopherol.

35. The lipid nanoparticle of claim 34, wherein the tocopherol is present in an amount between 0.5 and 15 mol%.

36. The lipid nanoparticle according to any one of claims 1 to 35, wherein the phospholipid is present in an amount between 0.5 and 3 mol%.

37. The lipid nanoparticle of claim 36, wherein the phospholipid is a phospholipid-cholesterol conjugate.

38. The lipid nanoparticle of claim 37, wherein the phospholipid-cholesterol conjugate is a phosphatidylcholine-cholesterol conjugate.

39. A method for delivering mRNA or vector DNA to produce a protein or peptide in the liver in vivo, the method comprising administering to a mammal a lipid nanoparticle having at least 45 mol% sterols or derivatives thereof, neutral lipids, and ionizable lipids, wherein the mRNA or vector DNA is encapsulated within the lipid nanoparticle, and wherein administration of the lipid nanoparticle results in liver-specific expression of the protein or peptide encoded by the mRNA or vector DNA, wherein the lipid nanoparticle increases the expression of the protein or peptide encoded by the mRNA or vector DNA in the liver by at least 20 times compared to the spleen.

40. A method for delivering siRNA or antisense oligonucleotides to silence a gene in the liver in vivo, the method comprising administering to a mammal a lipid nanoparticle having at least 45 mol% sterols or derivatives thereof, neutral lipids, and ionizable lipids, wherein mRNA is encapsulated within the lipid nanoparticle, and wherein administration of the lipid nanoparticle results in liver-specific silencing of a protein or peptide encoded by a nucleic acid sequence, wherein the lipid nanoparticle increases silencing of the nucleic acid in the liver by at least 5-fold compared to the spleen.

41. The method of claim 39, wherein the increased expression of a protein or peptide encoded by the mRNA in the liver compared to the spleen measured under otherwise identical conditions is at least 10% greater than the increased expression in the liver compared to the spleen in Onpattro LNP.

42. The method according to claim 40 or 41, wherein the neutral lipid content is between 0.25 and 10 mol%.

43. The method of claim 42, wherein the neutral lipid content is between 0.5 and 8 mol%.

44. The method of claim 43, wherein the neutral lipid content is less than 7 mol%.

45. The method of claim 44, wherein the neutral lipid content is less than 6 mol%.

46. ​​The method of claim 45, wherein the neutral lipid content is less than 5 mol%.

47. The method of claim 46, wherein the neutral lipid content is less than 4 mol%.

48. The method according to any one of claims 39 to 47, wherein the sterol or derivative thereof is present in an amount of 45 to 80 mol%.

49. The method of claim 45, wherein the sterol or derivative thereof is present in an amount of 49 to 65 mol%.

50. The method according to any one of claims 39 to 49, wherein the hydrophilic polymer-lipid conjugate is present in the lipid nanoparticle in an amount between 0.5 and 3 mol%.

51. The method of claim 50, wherein the hydrophilic polymer-lipid conjugate is present in the lipid nanoparticle in an amount between 0.5 and 2.0 mol%.